The UK’s National Institute for Health and Care Excellence (NICE) recommended Eli Lilly’s once-weekly insulin, Onswik (efsitora alfa), for NHS use.
This recommendation remains contingent on the treatment receiving formal marketing authorization.
Onswik reduces the injection burden for type 2 diabetes patients from daily to weekly doses.
Clinical trials demonstrated that Onswik matches the blood glucose control of daily insulins like degludec and glargine.
Weekly administration specifically benefits elderly patients and those with disabilities who require assistance with injections.
This decision facilitates national coverage for the new treatment across the United Kingdom.